Media headlines about X T L Biopharmaceuticals (NASDAQ:XTLB) have been trending somewhat positive this week, according to Accern. Accern rates the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. X T L Biopharmaceuticals earned a news impact score of 0.20 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 51.7867549436845 out of 100, meaning that recent media coverage is somewhat likely to have an impact on the stock’s share price in the next few days.
Shares of X T L Biopharmaceuticals (NASDAQ:XTLB) opened at $2.37 on Friday. X T L Biopharmaceuticals has a 12 month low of $1.93 and a 12 month high of $4.70.
TRADEMARK VIOLATION NOTICE: This story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/12/x-t-l-biopharmaceuticals-xtlb-getting-somewhat-favorable-news-coverage-report-finds.html.
X T L Biopharmaceuticals Company Profile
XTL Biopharmaceuticals Ltd. is a biopharmaceutical company. The Company focuses on the acquisition and development of pharmaceutical drugs for the treatment of medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE).
Receive News & Ratings for X T L Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X T L Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.